Show simple item record

dc.contributor.advisorRobert S. Langer.en_US
dc.contributor.authorGrislain, Jacques-Henryen_US
dc.contributor.otherSloan School of Management.en_US
dc.date.accessioned2016-09-30T19:34:23Z
dc.date.available2016-09-30T19:34:23Z
dc.date.copyright2016en_US
dc.date.issued2016en_US
dc.identifier.urihttp://hdl.handle.net/1721.1/104535
dc.descriptionThesis: S.M. in Management Studies, Massachusetts Institute of Technology, Sloan School of Management, 2016.en_US
dc.descriptionCataloged from PDF version of thesis.en_US
dc.descriptionIncludes bibliographical references (page 92).en_US
dc.description.abstractThe Biotechnology investment sector has been booming over the last ten years delivering substantial financial returns for public and private investors and most VC firms have been raising and deploying a lot of capital into fast-growing Biotechnology companies. However, it may seem paradoxical that the Biotechnology industry attracts increasingly more Venture Capital and Public funding whereas it is one of the riskiest and volatile sectors and most early-stage companies do not generate revenues for years and have large financial needs to cover expensive clinical trials. My research will focus on Biotechnology investments in the US and will cover the value chain of a Venture Capital firm with a competitive analysis, a detailed review of current funding trends, a performance review analysis and a study to explain why Boston has become the n°1 cluster for Biotechnology in the US. The study also includes feedbacks from 25 interviews conducted with Founders and CEOs of Biotechnology companies, Life Sciences experts, Scientists and Venture Capital investors.en_US
dc.description.statementofresponsibilityby Jacques-Henry Grislain.en_US
dc.format.extent94 pagesen_US
dc.language.isoengen_US
dc.publisherMassachusetts Institute of Technologyen_US
dc.rightsM.I.T. theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. See provided URL for inquiries about permission.en_US
dc.rights.urihttp://dspace.mit.edu/handle/1721.1/7582en_US
dc.subjectSloan School of Management.en_US
dc.titleThe venture capital in the biotechnology industryen_US
dc.typeThesisen_US
dc.description.degreeS.M. in Management Studiesen_US
dc.contributor.departmentSloan School of Management
dc.identifier.oclc958300137en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record